GILEAD SCIENCES, INC

GILD
Real-time Estimate Quote. Real-time Estimate  - 11/25 04:00:01 pm
59.945USD -0.51%
Business Summary
Healthcare
Pharmaceuticals & Medical Research
 Biotechnology & Medical Research
  Biotechnology & Medical Research
   Bio Therapeutic Drugs
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.5%): for the treatment of HIV, hepatitis B virus and hepatitis C virus (93.4% of net sales) and other (6.6%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.5%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (74.1%), Europe (17%) and other (8.9%).

Number of employees : 11 800 people.
Sales per Business
20182019
USD
(in Million)
%USD
(in Million)
%
Innovative Medicines 22,12799.6% 22,449100.6%
Sales per region
20182019
USD
(in Million)
%USD
(in Million)
%
United States 16,26973.2% 16,64574.6%
Europe 4,00618% 3,81117.1%
Other International 1,8528.3% 1,9938.9%
Managers
Name Title
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
William A. Lee Executive Vice President-Research
Merdad V. Parsey Chief Medical Officer
George Pratt Shultz Director-Emeritus
Gayle Edlund Wilson Independent Director
John Francis Cogan Lead Independent Director
Richard J. Whitley Independent Director
Kevin E. Lofton Independent Director
Per Wold-Olsen Independent Director
Shareholders
Name Equities %
Capital Research & Management Co. (Global Investors) 117,113,247 9.35%
The Vanguard Group, Inc. 98,734,165 7.88%
Putnam LLC 83,388,336 6.66%
Capital Research & Management Co. 64,780,000 5.17%
SSgA Funds Management, Inc. 56,993,329 4.55%
Capital Research & Management Co. (International Investors) 48,533,977 3.87%
Capital Research & Management Co. (World Investors) 39,342,449 3.14%
BlackRock Fund Advisors 32,846,421 2.62%
Geode Capital Management LLC 20,001,978 1.60%
Northern Trust Investments, Inc.(Investment Management) 16,081,206 1.28%
Company contact information
333 Lakeside Drive
CA 94404 San Mateo, California


Phone : +1 650 574 3000
Fax : +1 650 578 9264
web site : http://www.gilead.com
Markets and indexes
-
- Nasdaq Global Select Market
- Nasdaq 100 / S&P 100, S&P 500, Stoxx Americas 100, Stoxx Global 200
Stock Exchange Codes
- Bloomberg Code :  GILD:US
- Reuters Code :  GILD.O
- Datastream Code :  @GILD
Sector Bio Therapeutic Drugs
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.-7.28%75 525
VERTEX PHARMACEUTICALS-1.12%56 298
REGENERON PHARMACEUTICALS34.79%53 416
WUXI APPTEC CO., LTD.55.32%38 761
BIONTECH SE200.68%24 529
BEIGENE, LTD.54.55%23 352
GENMAB A/S49.17%23 080
ARGENX SE52.37%12 308
MYOKARDIA, INC.208.58%11 993
HUALAN BIOLOGICAL ENGINEERING INC.52.60%11 716
MIRATI THERAPEUTICS, INC.72.99%11 233
SAREPTA THERAPEUTICS, INC.4.70%10 662
NEUROCRINE BIOSCIENCES, INC.-12.90%8 951
ASCENDIS PHARMA A/S14.49%8 508
ULTRAGENYX PHARMACEUTICAL INC.178.34%7 865
DENALI THERAPEUTICS INC.250.29%7 317
BIOCON LIMITED47.62%6 941
ACCELERON PHARMA INC.115.18%6 874
ARROWHEAD PHARMACEUTICALS, INC.-4.79%6 183
KODIAK SCIENCES INC.69.56%6 150
PEPTIDREAM INC.-10.54%5 827
Brand Portfolio
CELL DESIGN LABS
CELL DESIGN LABS
EPITHERAPEUTICS
EPITHERAPEUTICS
FORTY SEVEN
FORTY SEVEN
GILEAD SCIENCES
GILEAD SCIENCES
KITE PHARMA
KITE PHARMA
LETAIRIS
LETAIRIS
NIMBUS APOLLO
NIMBUS APOLLO
» More brands of Gilead Sciences, Inc.